We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Commentary: Azathioprine as an adjuvant therapy in severe Graves' disease: a randomized controlled open-label clinical trial.
- Authors
Mittal, Madhukar; Rizvi, Azher
- Abstract
A commentary published in Frontiers in Endocrinology discusses a randomized controlled trial that examined the use of azathioprine as an adjuvant therapy in patients with severe Graves' disease. The study found a high remission rate of 87.5% among patients taking azathioprine in addition to conventional therapy. However, the authors raise concerns about inconsistencies in the remission criteria used, the unusually low remission rate among patients receiving conventional therapy alone, conflicting findings with different doses of azathioprine, and lack of clarity regarding the duration of follow-up in the study. The commentary suggests that further research is needed to better understand the effects of azathioprine in the management of Graves' disease.
- Subjects
GRAVES' disease; AZATHIOPRINE; CLINICAL trials; THYROID eye disease
- Publication
Frontiers in Endocrinology, 2024, p01
- ISSN
1664-2392
- Publication type
Article
- DOI
10.3389/fendo.2024.1342915